Table 2.
Acute and late toxicity (CTCAE v. 5.0) in patients who underwent 192Ir–based HDR-BT, using customized surface moulds for NMSC
| Toxicity | G1 | G2 | G3-G4 | Any G |
|---|---|---|---|---|
| Acute | ||||
| Dermatitis | 21 (52%) | 12 (30%) | 0 | 33 (82%)) |
| Ulceration | 9 (22%) | 2 (5%) | 0 | 11 (27%) |
| Pain | 10 (25%) | 0 | 0 | 10 (25%) |
| Dry skin | 5 (12%) | 0 | 0 | 5 (12%) |
| Infection | 1 (2%) | 0 | 0 | 1 (2%) |
| Late | ||||
| Fibrosis | 7 (17%) | 0 | 0 | 7(17%) |
| Telangiectasia | 3 (7%) | 0 | 0 | 3 (7%) |
| Atrophy | 6 (15%) | 0 | 0 | 6 (15%) |
| Hypopigmentation | 5 (12%) | 0 | 0 | 5 (12%) |
CTCAE – common terminology criteria for adverse events, 192Ir – radioactive isotope of iridium, HDR – high-dose-rate, BT – brachytherapy, NMSC – non melanoma skin cancer, G1 – grade 1, G2 – grade 2, G3 – grade 3, G4 – grade 4, G3–G4 – toxicities